Podcasts about Leach

Sign Up for Collective Membership: https://strengthtc.com/product/collective-membership-subscription/?utm_source=youtube&utm_medium=social&utm_campaign=video_descScott Leech (URI) on Modern Football S&C Programming: High/Low Weeks, Roster Turnover, Testing, and Contact PrepTim Caron hosts Scott Leech, Head Strength & Conditioning Coach at the University of Rhode Island, to discuss practical program design amid the realities of modern college football, including transfers, NIL, and shortened training windows. Leach explains how he assesses athletes' readiness to train, uses position and relative-strength standards, and structures off-season weeks with a flexible high/low approach to manage field demands. He outlines non-negotiables such as max-velocity exposures (90%+), jump testing, and quality strength work, and explains how metric trends guide deloads and expectations across phases. The conversation covers planning from the annual calendar down, evaluating daily sessions and entire off-seasons, integrating game-based conditioning and contact prep, using GPS to validate load, and the need to keep programming evolving rather than becoming static. Leach also shares where to find him and his “Grid Iron Warrior 2.0” resources.00:00 Introduction and Background01:54 Rivalries and High School Memories03:03 Hall of Fame Aspirations03:58 Program Design Philosophy04:40 Challenges in College Football Programming06:51 Assessment and Developmental Programs13:36 Training Structure and Flexibility18:48 Max Effort Training and Metrics22:01 Annual Planning and Adjustments24:07 Evolving Training Models and Challenges29:42 Facing Life's Challenges30:26 Evaluating Training Sessions32:50 Assessing Off-Season Effectiveness34:49 Adapting Training Programs38:06 Maintaining Program Flexibility44:41 Contact Prep and Games52:30 Impact on Wins and Losses

Tom talks with Justin Rowland and more.

Tom talks with Jeff Piecoro, Jack Pilgrim, and more.

Tom talks with Larry Vaught, Jeff Drummond, and Jenna Lifshen.

Dick Gabriel fills in and talks with Darren Headrick, Maggie Davis, and more.

What do you get when you blend fascinating facts and family fun? I think you know the answer. Facebook PatreonSee omnystudio.com/listener for privacy information.

COACH IS JOINED BY Dennis Dodd and Tony Barnhart to discuss the increasingly chaotic off-field landscape of college football, even as the on-field product remains as highly entertaining as ever. The trio dives into the current lack of formal employment and collective bargaining for athletes, noting that players are effectively playing for pay through Name, Image, and Likeness (NIL) endorsements. Dodd warns that any attempts to cap or cut this compensation could spark player strikes, pointing to past athlete protests at schools like Missouri, Michigan, and Penn State as definitive proof of their leverage. The group also breaks down the proposed Protect College Sports Act, describing the legislation as potentially hostile to the powerhouses in the SEC and Big Ten, while highlighting the heavy political pushback and scheduling hurdles it currently faces in Congress. The conversation then pivots to the College Football Hall of Fame and the controversial exclusion of the late Mike Leach. Dodd criticizes the Hall's rigid requirement of a .600 career winning percentage—a strict rule allegedly championed by former Yankees owner George Steinbrenner—which Leach narrowly missed with a .594, despite his undeniable and transformative impact on the game. The guests argue that this mandate arbitrarily blocks profoundly influential figures from receiving their proper recognition. The segment concludes on a humorous and candid note when Barnhart formally recuses himself from the Mike Leach debate, revealing his active role on the committee that handles Hall of Fame decisions, before cheerfully signing off from the broadcast.See omnystudio.com/listener for privacy information.

COACH IS JOINED BY Dennis Dodd and Tony Barnhart to discuss the increasingly chaotic off-field landscape of college football, even as the on-field product remains as highly entertaining as ever. The trio dives into the current lack of formal employment and collective bargaining for athletes, noting that players are effectively playing for pay through Name, Image, and Likeness (NIL) endorsements. Dodd warns that any attempts to cap or cut this compensation could spark player strikes, pointing to past athlete protests at schools like Missouri, Michigan, and Penn State as definitive proof of their leverage. The group also breaks down the proposed Protect College Sports Act, describing the legislation as potentially hostile to the powerhouses in the SEC and Big Ten, while highlighting the heavy political pushback and scheduling hurdles it currently faces in Congress. The conversation then pivots to the College Football Hall of Fame and the controversial exclusion of the late Mike Leach. Dodd criticizes the Hall's rigid requirement of a .600 career winning percentage—a strict rule allegedly championed by former Yankees owner George Steinbrenner—which Leach narrowly missed with a .594, despite his undeniable and transformative impact on the game. The guests argue that this mandate arbitrarily blocks profoundly influential figures from receiving their proper recognition. The segment concludes on a humorous and candid note when Barnhart formally recuses himself from the Mike Leach debate, revealing his active role on the committee that handles Hall of Fame decisions, before cheerfully signing off from the broadcast.See omnystudio.com/listener for privacy information.

Tom talks with Jack Givens, Justin Rowland, and Kendrick Haskins.

Tom talks with Mike DeCourcy and Brandon Ramsey.

Programledare: Dawid FjällPanel: Jesper Hofmann & Robin BerglundGäster på länk: Oskar MånssonGäster på plats: Les Big Byrd, Samuel Leach Holm & MygganRedaktion: Oliver Tommos Jernberg, Carl Hultin, Victor Enberg & William ÅbergAnsvarig utgivare: Dawid Fjäll Hosted on Acast. See acast.com/privacy for more information.

-We mentioned last week that Leach would be on the ballot---and should be voted in---he's joined on the ballot by Cam Newton and RobertGriffin III as names that should get in without hesitation-Other names from the past: Tavon Austin, Brad Banks, Adrian Clayborn, Rocky Calmus, Cris Carter, Dallas Clark, Ken Dorsey, Troy Edwards,Melvin Gordon, Percy Harvin, Josh Heupel, AJ Hawk, Sebastian Janikowski, Bruce Matthews, Marshawn Lynch, Kellen Moore, Colt McCoy andmore…which of those names do you think of as a Hall of Famer?Our Sponsors:* Check out Hims and use my code hims.com/EARLYBREAK for a great deal: https://www.hims.com* Check out Progressive: https://www.progressive.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Jon Wilner of The San Jose Mercury News and Wilner Hotline joins Dave Softy Mahler and Dick Fain to talk about Mike Leach’s high chances of making the Hall of Fame, the government trying to set rules for college football, the current media rights situation, the ongoing situation with Brandon Sorsby after his gambling troubles, the Rose Bowl kick time possibly changing to one hour earlier, and Greg Lewis on the Hall of Fame ballot.See omnystudio.com/listener for privacy information.

Tom talks with Larry Vaught, Dick Gabriel, and Travis Branham.

Read beyond the headlines! Support Local Journalism  https://www.spokesman.com/podcastoffer

Send us Fan MailSend us Fan MailIn this thought-provoking episode of Living the Dream with Curveball, we sit down with Norman Leach, a dynamic leader, educator, and author who has navigated the complexities of various industries while embracing lifelong learning and reinvention. Norman shares the wisdom imparted by his grandfather, emphasizing the importance of education and experience as tools that cannot be taken away. His adventurous spirit has led him to engage in business across 37 countries, speak multiple languages, and thrive in the eye of the storm during periods of change.Listeners will gain insight into Norman's journey, including his decision to step away from traditional corporate paths in search of fulfillment and joy in his work. He reflects on the significance of teamwork, the value of leading from the front, and the importance of embracing challenges rather than shying away from them. Norman's candid experiences in teaching reveal the diverse perspectives of learners and the joy of nurturing their growth.As he discusses the evolving landscape of AI and marketing, Norman highlights both the excitement and the concerns surrounding this transformative technology. He urges listeners to adapt and innovate, reminding us that the future belongs to those who are willing to let go of old paradigms and embrace new possibilities.Join us for an inspiring conversation filled with practical advice and encouragement for anyone looking to pursue their dreams and navigate the uncertainties of life.What You'll Learn in This Episode:- The impact of lifelong learning on personal and professional growth- Insights into leading through uncertainty and building effective teams- The role of teaching in understanding diverse perspectives- The opportunities and challenges presented by AI in marketing- The importance of letting go of old ways to embrace new possibilitiesFor more information on Norman Leach and his work, connect with him on LinkedIn as @Norman Leach, the Chaos Navigator. Don't miss out on this engaging episode that will inspire you to take bold steps towards your own dreams.Support the show

Tom talks with Ben Roberts, Adam Luckett and more.

​ @CodyLeachYT  joins us for a fun episode where we put different horror characters in the ring to face off against one another in what we call Horror Characters DeathmatchFind us on Patreon for spoiler talk, early access, and exclusiveshttps://www.patreon.com/c/scaretalk#horrormovies #horrorcharacters #michaelmyers #jasonvoorhees #freddykrueger #pennywise #jigsaw #normanbates #arttheclown #ghostface #leatherface #chucky #pinhead #m3gan

On this Salcedo Storm Podcast:Kenny Webster, comedian, brodcaster and all around great conservative! 

Tom talks with Jack Givens, Derek Terry and more.

The Herle Burly was created by Air Quotes Media with support from our presenting sponsor TELUS, as well as CN Rail, and the Public Service Alliance of Canada.Greetings, you curiouser and curiouser Herle Burly-ites! We're over a year into a new government and nobody could possibly argue there hasn't been a significant recalibration in the way Canada thinks about climate policy and environmental regulation.The public policy balance between the environment, pipelines, and project-building has shifted from what it was, say, back in 2018. So has the public's perception, by the way. Recent polling shows that Canadians now prioritize economic growth over environmental protection. All of this is what we'll explore today. From multiple angles. In 3 different individual conversations.First up ... Aaron Wherry, senior writer at the CBC ... to set the table on the issues between Ottawa and Alberta.Then … Rick Smith, President of the Canadian Climate Institute, for his perspective. We talk about emissions reduction, what's happening to the industrial carbon price, the clean energy economy and more.Finally … Andrew Leach, energy and environmental economist and professor at the University of Alberta, to explore the energy sector, particularly oil. The economic impact vs. opportunity cost of pipelines, and the tension between market forces and climate policy. Thank you for joining us on #TheHerleBurly podcast. Please take a moment to give us a rating and review on iTunes, Spotify, or your favourite podcast app.Watch episodes of The Herle Burly via Air Quotes Media on YouTube.The sponsored ads contained in the podcast are the expressed views of the sponsor and not those of the publisher.

Let's go

Tom talks with Dick Gabriel, CL Brown, and more.

Tom talks with Gary Parrish, Mike DeCourcy and more.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Tom talks with Larry Vaught, Darren Headrick, and more.

Tom talks with Ben Roberts and Keith Farmer.

Tom talks with Dick Gerardi, Randy Moss, and Jeff Drummond.

Tom talks with Justin Rowland, Jack Givens, and Darren Headrick.

From the beginning, the Hermes Family knew they were in the craftsmen business. Making products that last for generations. Dave Young: Welcome to the Empire Builders Podcast, teaching business owners the not-so-secret techniques that took famous businesses from mom-and-pop to major brands. Stephen Semple is a marketing consultant, story collector, and storyteller. I’m Stephen’s sidekick and business partner, Dave Young. Before we get into today’s episode, a word from our sponsor, which is, well, it’s us, but we’re highlighting ads we’ve written and produced for our clients. So here’s one of those. [Wagmore Garage Doors Ad] Dave Young: Welcome back to the Empire Builders Podcast. Dave Young here, along with Stephen Semple. And Stephen, just before he whispered the topic in, this tells you what Stephen thinks about me. He said, “Yeah. I’ll tell you this one, but I don’t think you’re going to know about it because it’s a really high-end fashion.” Yeah. Stephen Semple: It’s not exactly what I said. Dave Young: Not … Well, I’m telling the truth in a more powerful way. And as we call them in Nebraska, Hermès, but it’s Hermès. Say it for me. Stephen Semple: I think it’s Hermès because it’s French. Dave Young: Hermès? Hermès? Stephen Semple: Yeah. Dave Young: Is the H pronounced at the beginning or not? I don’t know. Stephen Semple: I think it would be very soft. Dave Young: Scarves and things like that, that’s all I know. Stephen Semple: Well, the big thing they’re known for is handbags. Dave Young: Things I don’t own is what they’re known for. Stephen Semple: Correct. Dave Young: And I will admit you were absolutely right to think that I probably don’t know a whole lot about these people or this brand. Stephen Semple: The more I looked into this company, the more interested I got on it because I got fascinated by some of the history. Dave Young: I got to share with you just how much I don’t know about them. You see this shirt I’m wearing as we record? Stephen Semple: Yes. Dave Young: This is from the fishing department at Walmart. Not the men’s clothing section. Fishing. And I- Stephen Semple: And, Dave- Dave Young: Here’s the other thing. Stephen Semple: Dave, you don’t fish, dude. Dave Young: I don’t fish. No, I don’t. I don’t fish at all. I stumbled across these shirts one time. I’m like, “I love these shirts.” But yeah, anyway, they’re not Hermès. Stephen Semple: So this is a really interesting company. It was founded in 1837 by Thierry Hermès. And he’s a German-born craftsman. And the company started in Paris. Now, what makes it super rare is here we are, close to 190 years later, and it’s still primarily owned by direct descendants of Thierry. Dave Young: Wow. Stephen Semple: There you go, Dave. Dave Young: Okay. That’s pretty cool. That’s a family business. Stephen Semple: That’s interesting on its own, isn’t it? Dave Young: Mm-hmm. Stephen Semple: So the family owns somewhere between 65 and 70% of the business, and is publicly traded at around a valuation of about $200 billion. Dave Young: That’s a lot of billion. Stephen Semple: That’s a couple of billion, isn’t it? Dave Young: Yeah. Wow. Okay. Stephen Semple: They only have like 70% of that 200 billion, so … Dave Young: Oh. Well, just downgraded their jet. Stephen Semple: Yeah. That’s it. So in 2010, the luxury giant LVMH tried to take the company over, and the family blocked it. There was a time where they tried to take over. And the CEO, Axel Dumas, is a sixth generation member of the Hermès family. So today, they have 300 stores. They do 14 billion EU, which is about 16 billion US in sales, which means they sell $50 million per store. Dave Young: I was going to say that’s not very many stores. Stephen Semple: No. And put in perspective, Gucci does about 25 million. Prada does half of that. Tiffany’s does about 15 million per store. $50 million per store. Dave Young: It’s got to be a front for something else. Stephen Semple: Now, their big product, so we talked about … Is this handbag called the Birkin bag. And the Birkin bag sells for anywhere from $10,000 to $100,000 per bag. Dave Young: Get out of town. Stephen Semple: Yeah. And often sells for more- Dave Young: Is it bottomless? Can you crawl into it? Stephen Semple: Seemingly, it’s a pretty big bag. I personally- Dave Young: Will it transport you to other dimensions? Stephen Semple: I personally have never known anybody who’s had one, so I can’t really comment. Dave Young: No. No. I just want to touch one. Stephen Semple: And here’s the other crazy thing, is they often sell for more on the secondary market. Dave Young: Sure. Stephen Semple: Yeah. Dave Young: Why not? Stephen Semple: They’re super- Dave Young: Because they only make a couple of them, or enough to sell. Stephen Semple: They’re super scarce. You cannot walk into a store and buy one. There’s a waiting list. Dave Young: Wow. Okay. Stephen Semple: Even celebrities, doesn’t matter who you are, have to get on the waiting list. They’ve really leaned into this whole idea of scarcity. Dave Young: Yeah. Stephen Semple: They’ve really leaned into it. Dave Young: How many billion dollars worth of scarcity? Stephen Semple: Oh, in terms of their sales? Dave Young: 300 stores. And how much per store? Stephen Semple: Well, 50 million a store. Dave Young: It doesn’t feel like scarcity, but when the handbags are 10,000 and up … Wow. Stephen Semple: And to this day, the leather bags use the original hand saddle stitching. Every bag is made by one person, beginning to end, handcrafted. Their scarves, which are also really known for, are hand screen printed. The edges are all hand rolled. And the CEO personally signs off on every product. Dave Young: All right. Stephen Semple: So there is this real high level of craftsmanship with it. So Thierry was born in 1801 in Krefeld, Germany. And at the time, that part of Germany was under the control of Bonaparte, which made him a French citizen. So that’s why though he was German-born, French citizen. Dave Young: Oh. Okay. Stephen Semple: And the town was known for textiles and was considered the city of velvet and silk. And in 1821, most of his family had died of famine and disease due to the war. So he moved to Normandy, where he learned the art of saddle and harness making under the Palmieri family. 1828, he married. And in 1837, he moved to Paris and opened an equestrian supply store. I’m going to butcher this. Dave Young: Of course you are. Stephen Semple: Rue Basse-du-Rempart. Dave Young: You said it perfectly. Stephen Semple: Okay. There we go. There, he made bridals, harnesses, carriage fittings using leather and wrought iron, right? And he became famous for a particularly strong saddle stitch that basically uses this opposite stitching. If one of the stitches broke, the other held. Dave Young: Now, here’s what I know about horses in Paris. Stephen Semple: Okay. Dave Young: Ain’t no cowboys over there. So again, this is the rich folk doing equestrian things and pulling carriages. Stephen Semple: That’s it. It was a mode of transportation. Dave Young: Yeah. The average folk are walking around the streets of Paris. Stephen Semple: Correct. Correct. It was the nobility who had horses and carriages. Now, that original stitch is still the stitch that’s being used today. Dave Young: Hey, if it works. Stephen Semple: Yeah. So this stitch is important to the history because to your point, horses and carriages were a mode of transportation. And, look, the roads were rough. Transportation was rough. So durability was really important. And his skill attracted the nobility. People like Eugénie, the wife of Napoleon III. So Thierry went on to win several medals for this design and his work. And he became known because his stitching did not break, the leather aged beautifully, and the workmanship was flawless under stress. So he died in 1878. And his son, Charles-Émile, took over. And like his dad, he was dedicated to this quality. The business expanded. They started creating more products, including these really large bags that could actually carry a saddle and the boots, right? Because- Dave Young: Wow. Okay. That is a big bag. Stephen Semple: Right? Because if you had a horse and you’re showing up, you take the saddle, you take the boots off, right? Dave Young: Yeah. Yeah. Stephen Semple: And it’s really considered the forerunner to this big handbag that they make today. So you’re asking, “Is it big?” It’s a big handbag. So the business growing. Dave Young: Everything but the horse. Stephen Semple: Yeah. Everything but the horse. That’s it. So the business is growing. The prestige is growing. They’re making these products for the horse and carriage industry. Then Charles travels to Canada. Dave Young: Oh. Okay. Stephen Semple: Okay. And he comes across this unique fastening system that’s being used for the canvas roof of the convertible Cadillac. It was a zipper. Dave Young: Oh. Yeah. The zipper. Uh-huh. Stephen Semple: So he took the idea back to France, and he applied for a patent to use the idea, and thus was born the Hermès fastener. It was innovative at the time. Dave Young: Okay. Stephen Semple: By the end- Dave Young: But it was a zipper? Stephen Semple: It’s a zipper. Dave Young: Okay. Stephen Semple: But it’s not a zipper. It’s the Hermès fastener. Dave Young: It’s the Hermès fastener. Yes. Get it right. Stephen Semple: Yeah. So by the end of World War II … This is another important part in terms of innovation because think about how many businesses that served the carriage trade that died. Dave Young: Well, sure. Yeah. Stephen Semple: Right? Dave Young: Because once we started all using cars and … I’m also thinking, man, this German-owned business in Paris in World War II, that’s got to be a tricky road to- Stephen Semple: Well, we’re not at World War II yet. End of World War I. Dave Young: Okay. Into World War- Stephen Semple: Into World War I. Dave Young: Oh, yeah. Okay. Kind of the same. Stephen Semple: He realizes that the car is going to take off. He notices the car. But what he also realizes, it’s a faster form of transportation. So it requires stronger materials and better fasteners because remember, the early cars didn’t have trunks that you put things in. You put a trunk on the back of the car and attached it all with fasteners. Dave Young: Right. So you need a trunk that could withstand being outdoors while a car drives it around. Stephen Semple: Correct. They did a collaboration with Bugatti where Bugatti commissioned a yellow trunk and yellow cowhide to match the first Bugatti Royale. Dave Young: Wow. Okay. Stephen Semple: Right. So this is a interesting thing. They did not change their business for the car. They refocused it. Dave Young: Stay tuned. We’re going to wrap up this story and tell you how to apply this lesson to your business right after this. [Using Stories To Sell] Dave Young: Let’s pick up our story where we left off. And trust me, you haven’t missed a thing. Stephen Semple: So this is a interesting thing. They did not change their business for the car. They refocused it. They leaned into the things they were already good at. And I think this is important because how many companies, again, were unable to pivot to the automobile business? Dave Young: I think of all the things in a car. Yeah. Eventually, we figured out we could actually put a trunk in the car instead of- Stephen Semple: Eventually. Dave Young: … carrying it on top. But you’ve also got all the upholstery, maybe the dashboard, maybe the steering wheel that would be wrapped in leather and need some fine stitching. So there’s lots of things that you could still do that show off your skill and your dedication to this kind of quality. Stephen Semple: Right. They didn’t ask, “What do we need to do differently?” They asked, “Where does their craftsmanship still matter?” Dave Young: Yeah. Stephen Semple: That’s the question they asked. Where does our craftsmanship still matter? Dave Young: And they realized that’s the business they were in, was craftsmanship and making things well. Stephen Semple: This is an important distinction to keep in mind that comes later. So 1922, they added their first handbag basically when Émile’s wife, she was like, “I’d like a scaled down version of this thing that you put boots and saddles in.” Dave Young: Don’t really need to carry my boots, but … Stephen Semple: But travel was also expanding at this time, so the handbags started becoming a needed accessory. 1950s, they added their orange box. So they took probably … And I’m going to guess they probably took inspiration from Tiffany’s Blue Box, and they created this orange box. Now, here’s an important part of the company’s history. It’s 1978. And Jean-Louis Dumas, the great-great-great-grandson of Thierry has taken over the company. And the company was stagnating. They still had loyal customers, but not enough of them. And here’s the advice that was given to them by investment bankers. Cut production costs by outsourcing production. Dave Young: Of course that’s the advice that was given to them by investment bankers. Stephen Semple: How many times we heard that advice? Dave Young: Yeah. Stephen Semple: But what was their DNA? Craftsmanship. Dave Young: Yeah. Stephen Semple: And, look, everybody will say, “Oh, you can outsource it, and you’ll still have the same quality.” He knew that to not to be true. He knew he would never be able to maintain quality the moment he did that. So how many companies would have resisted this? I don’t know of any others. I’m sure there’s others. But that was a big moment. And he said, “No, we’re not doing that.” Instead, what he decided to do was something that they rarely did, advertise. Dave Young: Yeah. Okay. Stephen Semple: But here’s what they did. They decide to advertise something different. It’s 1979. And they launched this campaign showing edgy, young … Remember, ’79. Edgy, young Parisian women wearing silk Hermès scarves, not in haute couture, wearing jeans. Dave Young: Yeah. There you go. Stephen Semple: Fits, but doesn’t fit. Picked a scarf. Expensive, but pretty much anybody could purchase. And all of a sudden, this accessory that made the jeans and everything look awesome. Where did you get that scarf? Dave Young: You could dress down, but people would still know. Stephen Semple: Bingo. Dave Young: I also think … I don’t know if this had a part in it or not, but that’s the era of Robin Leach’s Lifestyles of the Rich and Famous. Stephen Semple: Right. There you go. Dave Young: And so people had a fascination with this kind of thing there because of that show, right? That was always an interesting one to watch and to make fun of Robin Lynch, Leach, Robin Leach. Stephen Semple: Yeah. Leach. Yeah. So here’s the thing you could do. You could put on your jeans, you could put on a nice shirt, you could put on that scarf, and you’re looking like a Parisian model. They sold a crap ton of the scarfs. What they also knew is selling the scarves, people are now in their store, they’re going to see other things. Dave Young: Yeah. They’re going to start to want that bag. Stephen Semple: The advertising campaign was shocking. Dave Young: Really? Stephen Semple: Because it was just … Well, it was never done before. It was never this super high-end fashion going there. They were the first to do it. It was shocking, but changed the trajectory of the company. We could do a whole episode just on the scarves and the history of the handbags in terms of the things that they did for promoting it. But what I loved was he looked at it and he said, “There’s another option other than dropping production costs. What we need to do is we need to find new customers. How are we going to find new customers? We’re going to find new customers by reaching down, but we’re not going to reach down by making our products cheaper. We’re going to reach down by finding a product that if somebody really wants, they … Sure, $300, $400 scarf is crazy expensive, but can buy. And we’re going to make it glamorous. And, look, if we sell a whole pile of those scarves, we’re doing well.” Dave Young: So I may be wrong on this, but here’s what my Spidey-sense tells me. Who stole the idea of the DNA of the Hermès ads in the ’70s to repeat that thing where it’s, “We can make this expensive product desirable. And everybody will want it”? Stephen Semple: Ralph Lauren. Dave Young: Now I’m thinking iPods. Stephen Semple: Except he’s not expensive. Dave Young: I’m thinking iPod. The iPod. Stephen Semple: iPods. Interesting. Interesting. Dave Young: Thousand songs in your pocket. And the ads were sort of this every person with the white cord and the AirPods. Stephen Semple: Interesting. Interesting. Dave Young: But that’s the same notion, right? Stephen Semple: It is the same notion. Dave Young: This is the one little expensive thing that you can have and just make your life better. Stephen Semple: Yeah. Dave Young: Yeah. Stephen Semple: Well, it’s that whole idea of an indulgence. Dave Young: Mm-hmm. Absolutely. Stephen Semple: Right? This is an indulgence. I can go and I can treat myself. I will feel better. It’s special. It’s all these other things. And it’s that moment where you’re sort of like … It’s that whole idea of it’s an indulgence. And they figured out how to stay true to what they do. They still make the super expensive stuff, but were able to reach down into more mainstream, which is where you need to be in order to be successful long term. Dave Young: Yeah. You just want the people to really want the one thing. This is a great story. And now I’m wondering what color of Hermès cravat would go well with my Walmart fishing shirt. But here’s the problem. Here’s the problem. Stephen Semple: There’s so many problems. Dave Young: No. No. Well, I don’t even know where one of their stores is. So that’s probably by design. They don’t want me to know where one of their stores is. Stephen Semple: Where they will be- Dave Young: I’d wander around and touch things. Stephen Semple: Yeah. Where they would be would be in, again, the really super high-end malls [inaudible 00:18:49]. Dave Young: If you find a Tiffany store, you’ve found the Hermès store. Stephen Semple: You have. You have. But it’s funny because anytime I’ve known about the company, I’ve never really researched it because it was not- Dave Young: I’ve seen the name before. I’ve seen the name. Wondered how you pronounced it until fairly recently. Yeah. Stephen Semple: And seen the name, know about it. Then I came across a few things. And then literally how I got interested in it, I was researching Tiffany’s, and there was a little book on Tiffany’s that had some information in it that I thought I could use for the Tiffany’s episode. I bought the book, and Amazon said, “Those who have bought that book have also bought-“ Dave Young: Also like. Yeah. Hermès. Stephen Semple: “… this book.” Right? So I was like, “Oh, what the heck? Let’s add that to the cart.” Dave Young: Yeah. There you go. Stephen Semple: So I added it to the cart. And then I started reading through it, and I was like, “Wow. This is actually a really interesting company.” Dave Young: Very cool. Stephen Semple: Yeah. So I sort of stumbled across it kind of by accident. Dave Young: What’s the scarf cost? It’s got to be less than the leather bag. Stephen Semple: Oh, yes. Dave Young: Yeah. Stephen Semple: Yeah. Dave Young: So … Stephen Semple: I’m going to guess they’re three, $400. Dave Young: Okay. I’m just saying for the guys out there, this is one of those sleeper gifts, right? Get her a scarf from Hermès. Stephen Semple: I just Googled it. Canadian. They run from $500 to 750 bucks. Dave Young: Yeah. Yeah. I’m not saying do that instead of jewelry or something, but that’s a nice one you didn’t think of. Stephen Semple: It’s a special thing. Dave Young: Yeah. And she’s going to know more about it than you probably. Stephen Semple: And I remember doing the research on it. I was looking at them. They are beautiful and they’re all hand rolled and they are actually pretty spectacular. Dave Young: Awesome. All right. Hermès. Hermès. Hermès. Hermès. Hermès. Stephen Semple: Let’s go with Hermès. That sounds great. Dave Young: Hermès. Yeah. Stephen Semple: Hermès. Dave Young: It doesn’t sound quite as- Stephen Semple: I actually think if we’re probably going to … I think if we’re going to really do it correctly, it’s Hermès, I bet you. It’s just like … That H is just like- Dave Young: Hermès. Hermès is a diner somewhere, but- Stephen Semple: Just poking it. Dave Young: Hermès. Thank you for bringing us the Hermès story to the Empire Builders Podcast, Stephen. Stephen Semple: All right. Thanks, David. Dave Young: Thanks for listening to the podcast. Please share us. Subscribe on your favorite podcast app and leave us a big, fat, juicy five-star rating and review at Apple Podcasts. And if you’d like to schedule your own 90-minute empire building session, you can do it at empirebuildingprogram.com.

Tom talks with Krysten Peek, Mike DeCoucy, and more.

Tom talks with Dick Gabriel, Larry Vaught, and Kyle Wiltjer.

Tom talks with Mark Story and Adam Luckett.

Cheryl and Mariah discuss everything from medication decisions during pregnancy to adapting family life, traveling with chronic illness, managing expectations, and finding “micro moments” of joy along the way.  If you've ever worried that chronic illness might prevent you from building the life or family you want, this episode offers compassionate, practical encouragement that you do not have to give up on your goals, even if you have to adapt the path forward.  Episode at a glance: 00:00 Welcome Mariah Leach 02:18 Mariah's Diagnosis Story Recap 04:00 Why She Started the Mamas Facing Forward Group 13:41 Hive Mind Parenting Tips 17:51 Writing The Pregnancy Book 20:46 Medication Risk Tradeoffs 24:51 Pregnancy Remission Options 27:24 Book Research and Purpose 28:17 Parenting With Arthritis 31:43 Adapting Dreams and Grief 37:17 Tools and Book Picks Medical disclaimer:  All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Episode Sponsors Rheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected.  See all the details and join the program or waitlist now!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tom talks with Jon Hale, Justin Rowland, and more.

Tom talks with Mike DeCourcy and Kenny Rice.

Bruce and Eb are joined by Dr. Ken Liechty, a renowned fetal surgeon at Banner Health known for his groundbreaking work in fetal therapy and surgery. Arizona Senator Vince Leach also joins the conversation to discuss the current political landscape.

Dick Gabriel fills in and talks to Larry Vaught and Darrell Bird.

Billy Rutledge fills in to talk with Maggie Davis and Jeff Piecoro.

Tom talks with Dick Jerardi, Darren Headrick, and Donna Barton Brothers.

Tom talks with Justin Rowland, Kendrick Haskins, and more.